HRP20050041B1 - UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA - Google Patents

UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA

Info

Publication number
HRP20050041B1
HRP20050041B1 HRP20050041AA HRP20050041A HRP20050041B1 HR P20050041 B1 HRP20050041 B1 HR P20050041B1 HR P20050041A A HRP20050041A A HR P20050041AA HR P20050041 A HRP20050041 A HR P20050041A HR P20050041 B1 HRP20050041 B1 HR P20050041B1
Authority
HR
Croatia
Prior art keywords
pain
treatment
kinase inhibitors
iκb kinase
iκb
Prior art date
Application number
HRP20050041AA
Other languages
English (en)
Croatian (hr)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050041A2 publication Critical patent/HRP20050041A2/hr
Publication of HRP20050041B1 publication Critical patent/HRP20050041B1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20050041AA 2002-08-17 2003-08-05 UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA HRP20050041B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (2)

Publication Number Publication Date
HRP20050041A2 HRP20050041A2 (hr) 2006-04-30
HRP20050041B1 true HRP20050041B1 (hr) 2013-07-31

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050041AA HRP20050041B1 (hr) 2002-08-17 2003-08-05 UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA

Country Status (33)

Country Link
EP (1) EP1531819B1 (https=)
JP (1) JP4504811B2 (https=)
KR (2) KR101119845B1 (https=)
CN (1) CN100398107C (https=)
AR (1) AR043045A1 (https=)
AT (1) ATE418336T1 (https=)
AU (1) AU2003271555B2 (https=)
BR (1) BR0313555A (https=)
CA (1) CA2495455C (https=)
CO (1) CO5690585A2 (https=)
CR (1) CR7716A (https=)
CY (1) CY1108874T1 (https=)
DE (2) DE10237723A1 (https=)
DK (1) DK1531819T3 (https=)
EC (1) ECSP055609A (https=)
ES (1) ES2320118T3 (https=)
HR (1) HRP20050041B1 (https=)
IL (1) IL166780A (https=)
MA (1) MA27334A1 (https=)
MX (1) MXPA05001218A (https=)
MY (1) MY138059A (https=)
NO (1) NO334309B1 (https=)
OA (1) OA12907A (https=)
PL (1) PL212356B1 (https=)
PT (1) PT1531819E (https=)
RS (1) RS51878B (https=)
RU (1) RU2320338C2 (https=)
SI (1) SI1531819T1 (https=)
TN (1) TNSN05044A1 (https=)
TW (1) TWI325782B (https=)
UA (1) UA80837C2 (https=)
WO (1) WO2004022057A1 (https=)
ZA (1) ZA200500323B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎を治療するためのチエノピリジン
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT2787998T (lt) 2011-12-06 2017-02-10 Sanofi 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-karboksirūgšties [(s)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amido kristalinės formos
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
KR20170021884A (ko) * 2014-07-03 2017-02-28 사노피 골관절염에 연관된 통증의 치료에 사용하기 위한 2-(2-메틸아미노-피리미딘-4-일)-1h-인돌-5-카르복실산 [(s)-1-카르바모일-2-(페닐-피리미딘-2-일-아미노)-에틸]-아미드
CA3106124A1 (en) 2018-07-16 2020-01-23 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000610A1 (de) * 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Substituierte benzimidazole
WO2001030774A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Deutschland Gmbh Substituierte indole zur modulierung von nfkb-aktivität

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000610A1 (de) * 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Substituierte benzimidazole
WO2001030774A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Deutschland Gmbh Substituierte indole zur modulierung von nfkb-aktivität

Also Published As

Publication number Publication date
CN100398107C (zh) 2008-07-02
ECSP055609A (es) 2005-04-18
IL166780A0 (en) 2006-01-15
TWI325782B (en) 2010-06-11
OA12907A (en) 2006-10-13
CA2495455C (en) 2011-01-11
SI1531819T1 (sl) 2009-06-30
RS51878B (sr) 2012-02-29
KR20050058339A (ko) 2005-06-16
IL166780A (en) 2011-11-30
HRP20050041A2 (hr) 2006-04-30
JP2005539053A (ja) 2005-12-22
CR7716A (es) 2008-11-25
TW200417370A (en) 2004-09-16
EP1531819A1 (de) 2005-05-25
MXPA05001218A (es) 2005-05-16
KR101119845B1 (ko) 2012-02-28
WO2004022057A1 (de) 2004-03-18
MY138059A (en) 2009-04-30
HK1079426A1 (en) 2006-04-07
KR20110135428A (ko) 2011-12-16
RU2005107419A (ru) 2005-08-10
DE10237723A1 (de) 2004-07-08
PT1531819E (pt) 2009-02-18
UA80837C2 (uk) 2007-11-12
PL373568A1 (en) 2005-09-05
EP1531819B1 (de) 2008-12-24
MA27334A1 (fr) 2005-05-02
CY1108874T1 (el) 2014-07-02
PL212356B1 (pl) 2012-09-28
BR0313555A (pt) 2005-07-12
CN1674899A (zh) 2005-09-28
DK1531819T3 (da) 2009-04-20
CO5690585A2 (es) 2006-10-31
ES2320118T3 (es) 2009-05-19
RU2320338C2 (ru) 2008-03-27
NO334309B1 (no) 2014-02-03
ATE418336T1 (de) 2009-01-15
RS20050070A (sr) 2007-06-04
NO20051339L (no) 2005-05-03
AR043045A1 (es) 2005-07-13
ZA200500323B (en) 2006-02-22
AU2003271555A1 (en) 2004-03-29
CA2495455A1 (en) 2004-03-18
JP4504811B2 (ja) 2010-07-14
TNSN05044A1 (en) 2007-05-14
AU2003271555B2 (en) 2009-03-26
DE50310980D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
HRP20050041B1 (hr) UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
TW200714604A (en) Substituted heterocycles and the uses thereof
MEP60608A (en) INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE
SE0303180D0 (sv) Novel compounds
DK1853602T3 (da) Kemiske forbindelser
SE0302232D0 (sv) Novel Compounds
CY1108275T1 (el) Χημικες ενωσεις
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20091864L (no) Forbindelser for inhibering av mitotisk progresjon
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200601239A1 (ru) Замещённые хинолиновые соединения
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
ATE520668T1 (de) Sigmarezeptor-inhibitoren
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA200700909A1 (ru) Азаиндолкарбоксамиды
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150709

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20160805